Neurotech International (ASX:NTI) - CEO, Peter Griffiths
CEO, Peter Griffiths
Source: Accedian
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global
  • The proprietary cannabis strains will be used to treat neurological disorders such as autism, epilepsy and ADHD
  • Genetic profiling from Dolce seedlings have shown high levels of specific cannabinoids and low levels of THC which benefit children with neurological disorders
  • These strains compliment Neurotech’s Mente portable headband device which helps children with autism to relax and focus
  • Company shares have soared 60 per cent in the green and are trading for 1.6 cents each

Neurotech International (NTI) has secured an option to acquire an exclusive worldwide licence to use cannabis strains from Dolce Cann Global.

The proprietary cannabis strains will be medicinally used to treat neurological disorders such as autism, epilepsy and ADHD.

Dolce is an Australian developer of medicinal cannabis with proprietary genetics that are sourced from 13 rare landrace chemovars and bolstered over the last two decades using selective breeding techniques.

Recent profiling of leaf cuttings from 650 seedlings of Dolce genetics showed high levels of cannabinoids CBG, CBC, CBN and CBDV. Recent studies have shown the potential for these cannabinoids to target neurological disorders.

A key feature of Dolce’s strains is plant profiles with less than 0.3 per cent THC on average.

This is important, as Neurotech is focused on cannabis options for children with autism without the potential psychoactive effects of tetrahydrocannabinol (THC).

“With more evidence pointing to the potential for certain cannabinoids to help treat neurological disorders, it makes sense for us to explore this possibility through this agreement with leading cannabis genetics breeder Dolce and we are excited to get started on this research over the coming months,” Chairman Mark Davies said.

The company hopes to achieve a combined approach to autism treatment by potentially combining Dolce’s cannabis strains with its own Mente device. Mente is a portable headband that helps children with autism to relax, regulate and focus.

Project pathway

Neurotech has designed a three-stage program to investigate Dolce’s cannabis strains in treating neurological disorders.

Dolce plans to engage ACS Laboratories, a leading cannabis testing lab, to undergo genetic profiling of selected cannabis strains.

The studies will include dose-response studies, upper level of toxicity assessments, mechanism of action profiling and selecting top candidates.

Small-scale human clinical trials will also be conducted with a leading Australian University.

The third stage will comprise product formulation and final dose profiling to be done alongside Medipharm Australia.

Company shares have soared 60 per cent in the green and are trading for 1.6 cents each just before market close.

NTI by the numbers
More From The Market Herald

" Invex Therapeutics (ASX:IXC) receives UK approval to start phase III Presendin trial

Invex Therapeutics (ASX:IXC) has been given the tick of approval in the UK to start its…
Bluechiip (ASX:BCT) - Managing Director, Andrew McLellan

" Bluechiip (ASX:BCT) banks $1.09m R&D tax incentive refund

Bluechiip (ASX:BCT) has received $1.09 million research and development (R&D) tax incentive refund from the Australian…

" Oceania Healthcare (ASX:OCA) announces $500m sustainability-linked loan

Oceania Healthcare (ASX:OCA) has implemented its $500 million five-year sustainability-linked loan (SLL) to support its commitment…
Nyrada (ASX:NYR) - CEO, James Bonnar

" Nyrada (ASX:NYR) announces start date for cholesterol lowering program

Nyrada (ASX:NYR) announces its first-in-human study for cholesterol lowering is expected to begin during the first…